Novavax says U.S. FDA clears COVID vaccine doses for release
Tweet
Share
E-mail
FILE PHOTO: Vials labelled "VACCINE Coronavirus COVID-19" and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) - Vaccine maker Novavax on Tuesday said that the U.S. Food and Drug Administration had cleared a lot of its COVID vaccine for release in the United States, and it plans to ship doses to be distributed by the U.S. government in the coming days.
The FDA authorized the vaccine last week, but the manufactured doses were still awaiting quality testing before they could be released.
Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday voted unanimously to recommend use of the vaccine, and rollout of the shots can begin once the agency's director signs off on that recommendation.
(Reporting by Michael Erman; Editing by Mark Porter)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novavax's Nuvaxovid wins approval in U.S., EU, Japan for 2026-2027
- MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug
- BlossomHill to present BH-30643 trial data at lung cancer conference
Create E-mail Alert Related Categories
FDA, General News, ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
